Follow The Filings

Avidity Partners Management LP David Witzke

Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $624M
  • 45 holdings
  • 2026 Q2
  • +41.2% QoQ
  • Top 5 70.9%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 45 holdings

Top 5 70.9%, top 10 81.9%

  1. DNTH, Dianthus Therapeutics 32.8%
  2. CGON, CG Oncology 15.9%
  3. ORKA, Oruka Therapeutics 11.6%
  4. JBIO, Jade Biosciences 6.1%
  5. ELVN, Enliven Therapeutics 4.5%
  6. CATX, Perspective Therapeutics 3.4%
  7. AKTS, Aktis Oncology 2.5%
  8. PVLA 1.7%
  9. MOBI, Mobia Medical 1.7%
  10. RGEN, Repligen 1.7%
  11. Immunic 1.6%
  12. Senseonics 1.5%
  13. Other 15.0%

AUM over time

2026 Q2 $624M +41.2% QoQ
2021 Q3: $4.5B 2021 Q3: $4.5B
Q3 2021
2021 Q4: $4.7B, +4.5% QoQ 2021 Q4: $4.7B, +4.5% QoQ
Q4
2022 Q1: $4.8B, +1.9% QoQ 2022 Q1: $4.8B, +1.9% QoQ
Q1 2022
2022 Q2: $4.4B, −9.3% QoQ 2022 Q2: $4.4B, −9.3% QoQ
Q2
2022 Q3: $4.9B, +12.9% QoQ 2022 Q3: $4.9B, +12.9% QoQ
Q3
2022 Q4: $4.6B, −6.2% QoQ 2022 Q4: $4.6B, −6.2% QoQ
Q4
2023 Q1: $3B, −34.7% QoQ 2023 Q1: $3B, −34.7% QoQ
Q1 2023
2023 Q2: $2.9B, −5.0% QoQ 2023 Q2: $2.9B, −5.0% QoQ
Q2
2023 Q3: $2.5B, −13.3% QoQ 2023 Q3: $2.5B, −13.3% QoQ
Q3
2023 Q4: $2.7B, +10.5% QoQ 2023 Q4: $2.7B, +10.5% QoQ
Q4
2024 Q1: $3.1B, +13.0% QoQ 2024 Q1: $3.1B, +13.0% QoQ
Q1 2024
2024 Q2: $2.4B, −24.1% QoQ 2024 Q2: $2.4B, −24.1% QoQ
Q2
2024 Q3: $2B, −16.7% QoQ 2024 Q3: $2B, −16.7% QoQ
Q3
2024 Q4: $1B, −48.1% QoQ 2024 Q4: $1B, −48.1% QoQ
Q4
2025 Q1: $525M, −48.4% QoQ 2025 Q1: $525M, −48.4% QoQ
Q1 2025
2025 Q2: $502M, −4.4% QoQ 2025 Q2: $502M, −4.4% QoQ
Q2
2025 Q3: $439M, −12.5% QoQ 2025 Q3: $439M, −12.5% QoQ
Q3
2025 Q4: $347M, −21.0% QoQ 2025 Q4: $347M, −21.0% QoQ
Q4
2026 Q1: $442M, +27.4% QoQ 2026 Q1: $442M, +27.4% QoQ
Q1 2026
2026 Q2: $624M, +41.2% QoQ 2026 Q2: $624M, +41.2% QoQ
Q2

Book

2023 Q4 2023 Q3, filed 14 Feb, long equity only

Download CSV Download Excel All activity
ARVN, Arvinas 4.48%, was 2.07% Add +14.2% 2,985,117 $41.16 $123M +370,157 +$72M
BSX, Boston Scientific 3.98%, was 4.39% Reduce −8.5% 1,890,000 $57.81 $109M −175,800 +$187K
TMO, Thermo Fisher Scientific 3.53% New 182,600 $530.79 $97M +182,600 +$97M
ACHC 3.28%, was 2.02% Add +61.8% 1,156,692 $77.76 $90M +441,692 +$40M
NBIX, Neurocrine Biosciences 3.16%, was 2.95% Add +0.9% 658,000 $131.76 $87M +5,900 +$13M
SNDX, Syndax Pharmaceuticals 3.11%, was 1.65% Add +40.0% 3,950,000 $21.61 $85M +1,129,000 +$44M
NTRA, Natera 2.53%, was 1.60% Add +23.5% 1,110,000 $62.64 $70M +211,000 +$30M
DHR, Danaher 2.44%, was 1.76% Add +64.2% 290,000 $231.34 $67M +113,400 +$23M
THC, Tenet Healthcare 2.40%, was 2.56% Reduce −9.6% 871,000 $75.57 $66M −92,800 +$2.3M
Karuna Therapeutics 2.38% Reduce −28.1% 206,000 $316.51 $65M −80,700 +$17M
Fusion Pharmaceuticals 2.28%, was 0.61% Add +12.4% 6,500,328 $9.61 $62M +718,478 +$47M
JAZZ, Jazz Pharmaceuticals 2.19%, was 4.16% Reduce −38.7% 489,119 $123.00 $60M −308,381 −$43M
REGN, Regeneron 2.18%, was 1.92% Add +17.2% 68,000 $878.29 $60M +10,000 +$12M
CVS, CVS Health 2.13% New 740,000 $78.96 $58M +740,000 +$58M
Blueprint Medicines 2.07% Reduce −18.2% 615,000 $92.24 $57M −136,600 +$19M
Immunogen 1.98% Reduce −4.6% 1,829,215 $29.65 $54M −88,692 +$24M
IDYA, Ideaya Biosciences 1.97%, was 2.33% Reduce −29.1% 1,520,000 $35.58 $54M −624,971 −$3.8M
UTHR, United Therapeutics 1.90% New 237,202 $219.89 $52M +237,202 +$52M
RCKT, Rocket Pharmaceuticals 1.88%, was 1.31% Add +8.3% 1,719,103 $29.97 $52M +131,674 +$19M
Intra-Cellular Therapies 1.85% Reduce −11.4% 710,000 $71.62 $51M −91,100 +$9.1M
LLY, Eli Lilly 1.81%, was 1.62% Add +13.3% 85,000 $582.92 $50M +10,000 +$9.3M
BHVN, Biohaven 1.79% Reduce −10.7% 1,148,308 $42.80 $49M −137,092 +$16M
AVTR, Avantor 1.77% New 2,121,844 $22.83 $48M +2,121,844 +$48M
ZTS, Zoetis 1.73%, was 1.84% Reduce −8.4% 240,000 $197.37 $47M −22,100 +$1.8M
HUM, Humana 1.67%, was 2.16% Reduce −9.3% 100,000 $457.81 $46M −10,300 −$7.9M
ABBV, AbbVie 1.61% New 284,405 $154.97 $44M +284,405 +$44M
GPCR, Structure Therapeutics 1.60%, was 1.02% Add +116.0% 1,080,000 $40.76 $44M +580,000 +$19M
ALGN, Align Technology 1.56% New 155,800 $274.00 $43M +155,800 +$43M
Legend Biotech 1.50%, was 2.62% Reduce −29.2% 685,000 $60.17 $41M −282,000 −$24M
BDX, Becton Dickinson 1.47%, was 2.99% Reduce −42.2% 165,706 $243.83 $40M −121,094 −$34M
RARE 1.47%, was 0.78% Add +55.2% 844,500 $47.82 $40M +300,500 +$21M
MCK, McKesson 1.44%, was 2.91% Reduce −48.6% 85,500 $462.98 $40M −80,800 −$33M
XENE, Xenon Pharmaceuticals 1.37%, was 0.44% Add +153.9% 815,993 $46.06 $38M +494,593 +$27M
SGRY, Surgery Partners 1.36%, was 1.58% Reduce −12.9% 1,165,932 $31.99 $37M −172,068 −$1.8M
AXSM, Axsome Therapeutics 1.33%, was 0.84% Add +54.8% 459,400 $79.59 $37M +162,600 +$16M
CRBU, Caribou Biosciences 1.33%, was 1.16% Add +5.1% 6,360,212 $5.73 $36M +310,000 +$7.5M
PCVX, Vaxcyte 1.30%, was 1.55% Reduce −24.6% 570,137 $62.80 $36M −186,028 −$2.7M
NMRA, Neumora Therapeutics 1.24%, was 1.02% Add +10.6% 1,990,632 $17.05 $34M +190,632 +$8.5M
MIRM, Mirum Pharmaceuticals 1.23% Hold 1,142,850 $29.52 $34M — —
UNH, UnitedHealth Group 1.12%, was 2.28% Reduce −47.9% 58,500 $526.47 $31M −53,700 −$26M
PRVA, Privia Health Group 1.08%, was 1.43% Reduce −16.7% 1,287,000 $23.03 $30M −258,100 −$5.9M
ISRG, Intuitive Surgical 1.05% New 85,000 $337.36 $29M +85,000 +$29M
LNTH, Lantheus 0.86%, was 1.56% Reduce −31.9% 380,000 $62.00 $24M −178,400 −$15M
ANTX, An2 Therapeutics 0.85%, was 0.71% Add +4.6% 1,140,000 $20.49 $23M +50,600 +$5.8M
Ac Immune 0.81%, was 0.34% Add +50.5% 4,469,080 $5.00 $22M +1,499,280 +$14M
ARWR, Arrowhead Pharmaceuticals 0.80%, was 1.15% Reduce −32.9% 714,000 $30.60 $22M −349,897 −$6.7M
Immunocore 0.75% Reduce −13.8% 300,200 $68.32 $21M −48,000 +$2.4M
CRNX 0.69%, was 0.73% Reduce −13.3% 529,000 $35.58 $19M −81,000 +$680K
PHAT, Phathom Pharmaceuticals 0.57% Add +6.4% 1,721,580 $9.13 $16M +104,280 −$1.1M
Holding 0.57% Reduce −5.9% 780,900 $19.88 $16M −49,400 +$2M

Showing top 50 of 71 by value

Exits / last held

Gone since 2023 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
CI, Cigna 2.39% Exit 0 $286.07 $59M −207,700 −$59M
Sarepta Therapeutics 2.20% Exit 0 $121.22 $55M −450,000 −$55M
MLTX, Moonlake Immunotherapeutics 1.78% Exit 0 $57.00 $44M −777,172 −$44M
ZNTL, Zentalis Pharmaceuticals 1.70% Exit 0 $20.06 $42M −2,100,000 −$42M
DXCM, DexCom 1.42% Exit 0 $93.30 $35M −377,700 −$35M
BIIB, Biogen 1.19% Exit 0 $257.01 $30M −115,400 −$30M
HCA, HCA Healthcare 1.14% Exit 0 $245.98 $28M −114,800 −$28M
UHS, Universal Health Services 0.92% Exit 0 $125.73 $23M −182,000 −$23M
Curevac 0.86% Exit 0 $6.83 $21M −3,116,100 −$21M
PRTA, Prothena 0.74% Exit 0 $48.25 $18M −382,305 −$18M
ROIV, Roivant Sciences 0.71% Exit 0 $11.68 $18M −1,503,302 −$18M
Ventyx Biosciences 0.50% Exit 0 $34.73 $12M −354,900 −$12M
SDGR, Schrodinger 0.45% Exit 0 $28.27 $11M −399,000 −$11M
Rayzebio 0.45% Exit 0 $22.20 $11M −500,000 −$11M
PACB 0.35% Exit 0 $8.35 $8.6M −1,034,294 −$8.6M
Alpine Immune Sciences 0.30% Exit 0 $11.45 $7.5M −657,280 −$7.5M
Gritstone Bio 0.19% Exit 0 $1.72 $4.7M −2,733,800 −$4.7M
ATEC, Alphatec 0.16% Exit 0 $12.97 $4M −309,400 −$4M
Nanostring Technologies 0.16% Exit 0 $1.72 $4M −2,299,100 −$4M
Verve Therapeutics 0.15% Exit 0 $13.26 $3.8M −285,334 −$3.8M
ALT, Altimmune 0.12% Exit 0 $2.60 $3M −1,159,900 −$3M

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2023 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 45 $624M +41.2% 13F-HR 8/14/2026 000179182726000005
2026 Q1 45 $494M — new holds 5/28/2026 000179182726000004
2026 Q1 46 $442M +27.4% 13F-HR 5/13/2026 000179182726000003
2025 Q4 39 $347M −21.0% 13F-HR 2/13/2026 000179182726000002
2025 Q3 43 $439M −12.5% 13F-HR 11/14/2025 000179182725000008
2025 Q2 56 $502M −4.4% 13F-HR 8/14/2025 000179182725000007
2025 Q1 67 $525M −48.4% 13F-HR 5/15/2025 000179182725000005
2024 Q4 63 $1B −48.1% 13F-HR 2/14/2025 000179182725000002
2024 Q3 81 $2B −16.7% 13F-HR 11/14/2024 000179182724000011
2024 Q2 85 $2.4B −24.1% 13F-HR 8/14/2024 000179182724000007
2024 Q1 90 $3.1B +13.0% 13F-HR 5/15/2024 000179182724000004
2023 Q4 74 $2.7B +10.5% 13F-HR 2/14/2024 000179182724000002
2023 Q3 83 $2.5B −13.3% 13F-HR 11/14/2023 000179182723000006
2023 Q2 93 $2.9B −5.0% 13F-HR 8/14/2023 000179182723000004
2023 Q1 83 $3B −34.7% 13F-HR 5/15/2023 000179182723000003
2022 Q4 85 $4.6B −6.2% 13F-HR 2/14/2023 000179182723000002
2022 Q3 97 $4.9B +12.9% 13F-HR 11/14/2022 000179182722000008
2022 Q2 82 $4.4B −9.3% 13F-HR 8/15/2022 000179182722000006
2022 Q1 92 $4.8B +1.9% 13F-HR 5/16/2022 000179182722000004
2021 Q4 97 $4.7B +4.5% 13F-HR 2/14/2022 000179182722000002
2021 Q3 105 $4.5B — 13F-HR 11/15/2021 000179182721000006

About

Avidity Partners Management LP

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Avidity Partners Management LP
Notable person
David Witzke
Location
Dallas, TX
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf